Transcode Therapeutics Inc (RNAZ) Stock Price, Quote & News

Company Profile

TransCode Therapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing drugs and diagnostics for treating and identifying cancer. The company's lead therapeutic candidate comprises TTX-MC138 that targets microRNA-10b, a master regulator of metastatic cell viability in various cancers comprising breast, pancreatic, ovarian, colon cancer, glioblastomas, and others. Its preclinical programs include TTX-siPDL1, an siRNA-based modulator of programmed death-ligand 1 and t...

Industry: Biotechnology

Sector: Healthcare

Phone: 857 837 3099

Website: www.transcodetherapeutics.com

Address:

6 Liberty Square, Suite 2382, Boston, United States

ShadowSnake Feb. 24 at 3:35 PM

$RNAZ looks like today is the day I swallow my pride and take the loss… pos stock…GLTYA

1 · Reply

Sasuke7x Feb. 24 at 3:01 PM

Caught a few of @TheMorningStew alerts over the last few weeks that went crazy! Give him a follow 🔥 $RNAZ $QNRX $NIO $NAK Discounts

0 · Reply

Scoty_D Feb. 24 at 2:12 PM

$RNAZ

0 · Reply

TheMorningStew Feb. 24 at 11:28 AM

$RNAZ could go 13+ soon

1 · Reply

Hovius Feb. 24 at 11:14 AM

$RNAZ good news.. will it drop? https://ir.transcodetherapeutics.com/2026-02-23-TransCode-Therapeutics-Announces-Publication-of-Preclinical-Testing-of-RIG-I-Immunotherapeutic-Candidate-Supporting-Further-Development

0 · Reply

ShadowSnake Feb. 19 at 9:35 PM

$RNAZ $20!!!!

0 · Reply

Howegainz Feb. 19 at 9:12 PM

$RNAZ is cooking up something on low… The price action is giving me upcoming runner vibes.

0 · Reply

Hovius Feb. 19 at 9:00 PM

$RNAZ Bipolar stock…

0 · Reply

rock_it_stocks Feb. 14 at 9:29 PM

$RNAZ There is a plethora of information regarding TTX's ability to bypass the "liver trap". The small 20nm+/- size of TTX's tunable iron oxide nanoparticle, described as "Inhibitory Oligonucleotide Conjugated Nanoparticle", gains access to tumors and metastases and avoids early clearance by the kidneys and liver.

1 · Reply

Bio_Be_Dirty Feb. 13 at 6:56 PM

$RNAZ you got RNazzled

1 · Reply

TransCode Therapeutics Announces Publication of Preclinical Testing of RIG-I Immunotherapeutic Candidate Supporting Further Development

Feb 5, 2026, 8:04 AM EST - 19 days ago

TransCode Therapeutics and Quantum Leap Announce Submission of IND Amendment for Phase 2a Clinical Trial with TTX-MC138

Jan 6, 2026, 8:01 AM EST - 7 weeks ago

TransCode Therapeutics Announces Publication of Preclinical Data Supporting Therapeutic Potential of TTX-MC138 in Glioblastoma

Dec 22, 2025, 8:01 AM EST - 2 months ago

TransCode Therapeutics Expands Leadership with Appointment of Jack E. Stover to Board of Directors

Dec 11, 2025, 8:05 AM EST - 2 months ago

TransCode Therapeutics and Quantum Leap Healthcare Collaborative Launch a Phase 2a dose-expansion trial with TTX-MC138, following positive readouts from TransCode's Phase 1 trial

Nov 17, 2025, 8:01 AM EST - 3 months ago

TransCode Therapeutics Expands Executive Team with Appointment of Dr. Michel Janicot as Senior Development Officer

Oct 14, 2025, 8:06 AM EDT - 4 months ago

TransCode Therapeutics presents preliminary data from its completed Phase 1a study with TTX-MC138 in metastatic disease at ESMO

May 28, 2025, 8:00 AM EDT - 9 months ago

TransCode Therapeutics Appoints Dr. Phillip D. Zamore to Science Advisory Board

May 8, 2025, 8:05 AM EDT - 10 months ago

TransCode Therapeutics Successfully Completes Initial Dosing of Patients in Cohort 4 of Phase 1a Clinical Trial; No Dose Limiting Toxicities Reported

May 5, 2025, 5:07 PM EDT - 10 months ago

TransCode Therapeutics Announces Effective Date for 1-for-28 Reverse Stock Split

May 2, 2025, 4:10 PM EDT - 10 months ago

TransCode Therapeutics Announces 1-for-28 Reverse Stock Split

May 1, 2025, 9:01 AM EDT - 10 months ago

TransCode Therapeutics Reports Further Progress on Phase 1a Clinical Trial with No Dose Limiting Toxicities Reported in Patients with Metastatic Cancer

Apr 21, 2025, 4:37 PM EDT - 11 months ago

TransCode Therapeutics, Inc. Announces Adjournment of Special Meeting and Information for Adjourned Special Meeting

Mar 27, 2025, 4:37 PM EDT - 11 months ago

TransCode Therapeutics Announces Initial Dosing in Fourth Cohort of Phase 1 Clinical Trial with TTX-MC138

Mar 25, 2025, 6:24 PM EDT - 11 months ago

TransCode Therapeutics, Inc. Announces Closing of Registered Direct Offering

Mar 23, 2025, 11:11 PM EDT - 1 year ago

TransCode Therapeutics, Inc. Announces Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Mar 13, 2025, 7:47 AM EDT - 1 year ago

TransCode Therapeutics Announces Safety Review Committee Approval to Open Fourth Cohort in Phase I/II Clinical Trial

Feb 25, 2025, 4:15 PM EST - 1 year ago

TransCode Therapeutics, Inc. Announces Results of Special Meeting

Feb 6, 2025, 8:00 AM EST - 1 year ago

TransCode Therapeutics Announces Completion of Cohort 3 Initial Dosing with Lead Candidate in Phase 1 Clinical Trial

Jan 14, 2025, 8:00 AM EST - 1 year ago

TransCode Therapeutics Announces First Patient Dosed in Third Cohort with Lead Candidate in Phase 1 Clinical Trial

Jan 7, 2025, 8:00 AM EST - 1 year ago

Nasdaq Determines That TransCode Therapeutics Has Regained Compliance with Continued Listing Requirements

Dec 18, 2024, 8:00 AM EST - 1 year ago

TransCode Therapeutics Announces Safety Review Committee Approval of Opening Third Cohort and Preliminary Results from First Cohort in Phase 1 TTX-MC138 Clinical Trial

Nov 29, 2024, 4:25 PM EST - 1 year ago

TransCode Therapeutics Announces Effective Date for 1-for-33 Reverse Stock Split

Nov 27, 2024, 7:00 AM EST - 1 year ago

TransCode Therapeutics, Inc. Announces $8 Million Private Placement

Nov 5, 2024, 7:00 AM EST - 1 year ago

TransCode Therapeutics Announces Nasdaq Extension to Regain Compliance

Sep 17, 2024, 7:00 AM EDT - 1 year ago

TransCode Therapeutics Announces First Patients Treated in Phase 1 Clinical Trial with First-in-Class Lead Therapeutic Candidate

Sep 5, 2024, 7:00 AM EDT - 1 year ago

TransCode Therapeutics Awarded $2 Million NIH Grant to Support Clinical Evaluation of Lead Candidate

Jul 24, 2024, 4:05 PM EDT - 1 year ago

TransCode Therapeutics, Inc. Announces Closing of Public Offering

Jul 22, 2024, 10:30 PM EDT - 1 year ago

TransCode Therapeutics, Inc. Announces Pricing of Public Offering

Jul 22, 2024, 4:07 PM EDT - 1 year ago

TransCode Therapeutics, Inc. Announces Proposed Public Offering of Common Stock

May 29, 2024, 9:15 AM EDT - 1 year ago

TransCode Therapeutics Reports Positive Data from First-in-Human Clinical Study Using Novel Lead Therapeutic Candidate, TTX-MC138

May 13, 2024, 8:30 AM EDT - 1 year ago

TransCode Therapeutics Open Letter to Shareholders

Apr 15, 2024, 9:00 AM EDT - 2 years ago

TransCode Therapeutics Announces FDA Clearance To Initiate Phase 1/2 Clinical Trial with TTX-MC138 in Patients with Advanced Solid Tumors

Apr 3, 2024, 9:10 AM EDT - 2 years ago

TransCode Therapeutics Reports 2023 Results; Provides Business Update

Mar 28, 2024, 8:30 AM EDT - 2 years ago

TransCode Therapeutics Announces Appointment of Daniel Vlock, M.D., as Chief Medical Officer

Mar 11, 2024, 9:00 AM EDT - 2 years ago

TransCode Therapeutics and Akribion Genomics Report Progress Developing CRISPR-Derived Technology for Cancer Treatment

Mar 6, 2024, 4:15 PM EST - 2 years ago

TransCode Therapeutics To Present At 2024 RNA Leaders Europe Congress

Feb 20, 2024, 8:00 AM EST - 2 years ago

TransCode Therapeutics Reports Publication of United States Patent Application Covering TransCode's RIG-I Agonist Immunotherapeutic

Jan 31, 2024, 4:05 PM EST - 2 years ago

Nasdaq Determines TransCode Therapeutics Compliance with Minimum Stockholders' Equity Requirement and Continued Listing on The Nasdaq Stock Market

Jan 29, 2024, 8:30 AM EST - 2 years ago

TransCode Therapeutics and Debiopharm Announce Collaboration to Develop Targeted Nucleic Acid Therapeutics for Cancer

Jan 22, 2024, 4:45 PM EST - 2 years ago

TransCode Therapeutics Announces Closing of $7.25 Million Public Offering

Jan 18, 2024, 1:27 PM EST - 2 years ago

TransCode Therapeutics Announces Pricing of $7.25 Million Public Offering

Jan 12, 2024, 4:05 PM EST - 2 years ago

TransCode Therapeutics Reports Further Restructuring to Reduce Expenses and Increased Focus on Planned Phase 1 Clinical Trial, Retirement of CEO

Jan 11, 2024, 8:00 AM EST - 2 years ago

TransCode Therapeutics Announces 1-for-40 Reverse Stock Split

Jan 4, 2024, 8:05 AM EST - 2 years ago

TransCode Therapeutics Publishes Open Letter Outlining Company's Progress and Objectives

Dec 12, 2023, 8:30 AM EST - 2 years ago

TransCode Therapeutics Reports Positive Pre-Clinical Results in Metastatic Pancreatic Cancer with its Lead Candidate, TTX-MC138

Dec 5, 2023, 9:00 AM EST - 2 years ago

TransCode Therapeutics To Present Phase 0 Data at 2023 San Antonio Breast Cancer Symposium

Dec 4, 2023, 4:10 PM EST - 2 years ago

TransCode Therapeutics Announces Closing of $1.2 Million Registered Direct Offering of Common Stock Priced At-The-Market under Nasdaq Rules

Nov 30, 2023, 2:53 PM EST - 2 years ago

TransCode Therapeutics Announces $1.2 Million Registered Direct Offering of Common Stock Priced At-The-Market under Nasdaq Rules

Nov 14, 2023, 4:30 PM EST - 2 years ago

TransCode Therapeutics Reports Third Quarter 2023 Results; Provides Business Update

ShadowSnake Feb. 24 at 3:35 PM

$RNAZ looks like today is the day I swallow my pride and take the loss… pos stock…GLTYA

1 · Reply

Sasuke7x Feb. 24 at 3:01 PM

Caught a few of @TheMorningStew alerts over the last few weeks that went crazy! Give him a follow 🔥 $RNAZ $QNRX $NIO $NAK Discounts

0 · Reply

Scoty_D Feb. 24 at 2:12 PM

$RNAZ

0 · Reply

TheMorningStew Feb. 24 at 11:28 AM

$RNAZ could go 13+ soon

1 · Reply

Hovius Feb. 24 at 11:14 AM

0 · Reply

ShadowSnake Feb. 19 at 9:35 PM

$RNAZ $20!!!!

0 · Reply

Howegainz Feb. 19 at 9:12 PM

$RNAZ is cooking up something on low… The price action is giving me upcoming runner vibes.

0 · Reply

Hovius Feb. 19 at 9:00 PM

$RNAZ Bipolar stock…

0 · Reply

rock_it_stocks Feb. 14 at 9:29 PM

1 · Reply

Bio_Be_Dirty Feb. 13 at 6:56 PM

$RNAZ you got RNazzled

1 · Reply

FrostFuzz Feb. 12 at 10:49 PM

$RNAZ

0 · Reply

IAmMsMoneyMaker Feb. 10 at 8:14 PM

$PHGE $RNAZ I SAID IT WOULD WAKE UP…TIMING! ⏳ ⌛️ ALSO…$ECDA SOON!!!

0 · Reply

marvelousTrades Feb. 9 at 10:18 PM

$RGNX move over to $RNAZ

0 · Reply

Godwins26 Feb. 9 at 9:55 PM

After hours Watchlist 😊🚀 $TIRX this bout to fly pump it 😁 $RNAZ $PLSE $AXTI $ELVR

0 · Reply

Godwins26 Feb. 9 at 9:39 PM

Watchlist 🚀 $TIRX we still holding 100Million vol 🚀 $RNAZ $PLSE $AXTI $ELVR

0 · Reply

Godwins26 Feb. 9 at 9:38 PM

$TIRX we still holding 100Million vol 🚀 $RNAZ $PLSE $AXTI $ELVR

0 · Reply

ShadowSnake Feb. 9 at 8:43 PM

$RNAZ please run to $20+

0 · Reply

ShadowSnake Feb. 9 at 7:21 PM

$RNAZ $20?!

0 · Reply

harambe_reborn Feb. 9 at 7:05 PM

$RNAZ trying to launch huge spread trading thin

0 · Reply

ScalperEdge Feb. 9 at 11:37 AM

$RNAZ is an RNA therapeutics or diagnostics company; following the mRNA vaccine success, the field is hot, but delivering RNA to tissues beyond the liver remains a significant technical challenge.

0 · Reply

LunarCycle Feb. 8 at 12:29 AM

$RNAZ On February 6, 2026, PRHI announced the start of a rights offering for existing shareholders. $SKYQ Sky Quarry announced the completion of high-impact system upgrades at its Foreland Refinery in Nevada.

0 · Reply

phantomtrader75 Feb. 6 at 3:03 PM

$RNAZ per usual. It would have been better not to have any good news.

1 · Reply

Market Cap	8.89M
Revenue (ttm)	0.00
Net Income (ttm)	-16.75M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	50,800
Avg Vol	310,976
Day's Range	N/A - N/A
Shares Out	917,000.00
Stochastic %K	44%
Beta	1.55
Analysts	Strong Buy
Price Target	$10.00